CSIMarket
 
Myriad Genetics Inc   (MYGN)
Other Ticker:  
 
 
Price: $22.1800 $1.25 5.972%
Day's High: $22.21 Week Perf: -3.27 %
Day's Low: $ 20.59 30 Day Perf: 3.69 %
Volume (M): 868 52 Wk High: $ 24.21
Volume (M$): $ 19,250 52 Wk Avg: $19.97
Open: $21.03 52 Wk Low: $13.82



 Market Capitalization (Millions $) 1,836
 Shares Outstanding (Millions) 83
 Employees 2,700
 Revenues (TTM) (Millions $) 753
 Net Income (TTM) (Millions $) -263
 Cash Flow (TTM) (Millions $) 75
 Capital Exp. (TTM) (Millions $) 73

Myriad Genetics Inc
Myriad Genetics Inc.
is a leading biotechnology company in the United States that specifically focuses on the development and commercialization of molecular diagnostic tests.
The company is based in Salt Lake City, Utah and was founded in 1991.
Myriad Genetics is widely recognized for its innovative diagnostic tests, which help assess the risk of developing certain diseases, including inherited cancers, cardiovascular diseases, neurological disorders, and other genetic conditions.
The company has developed several proprietary technologies that enable its diagnostic tests to provide highly accurate and reliable results.
Myriad Genetics' most well-known product is its BRACAnalysis test, which is used to identify mutations in the BRCA1 and BRCA2 genes.
These mutations have been linked to breast and ovarian cancer, and the BRACAnalysis test is a key tool in helping healthcare professionals assess patients' risk of developing these diseases.
Myriad Genetics has also developed a range of other diagnostic tests, including its myRisk Hereditary Cancer test, which assesses the risk of developing several hereditary cancers using a multi-gene panel.
The company has also expanded into the field of companion diagnostics, working with pharmaceutical companies to develop tests that can identify patients who are likely to respond to specific treatments.
In addition to its diagnostic products, Myriad Genetics also operates a research and development division, which is dedicated to discovering new diagnostic and therapeutic technologies.
Myriad Genetics has received numerous awards and honors for its innovative work, including being named one of the world's most innovative companies by Forbes magazine.
As of 2021, Myriad Genetics has over 2,600 employees worldwide and its products are used in over 100 countries.
The company remains committed to advancing genetic testing and personalized medicine, with a focus on providing patients and healthcare professionals with the most accurate and reliable diagnostic information possible.


   Company Address: 322 North 2200 West, Salt Lake City 84116 UT
   Company Phone Number: 584-3600   Stock Exchange / Ticker: NASDAQ MYGN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Myriad Genetics Inc

Revolutionizing Cancer Monitoring: Myriad Genetics Inc. Makes Strides in MRD Research and Financial Performance for Q4 2023

r/>Myriad Genetics Inc., a leading molecular diagnostics company, recently announced its participation in an innovative clinical trial that aims to transform the way we monitor minimal residual disease (MRD) across different types of cancer. This collaboration with the National Cancer Center Hospital East in Japan marks a significant milestone in cancer research. By utilizing Myriad's cutting-edge Precise MRD test, researchers aim to evaluate the wide-ranging applicability of MRD monitoring.
Financial Performance for Q4 2023:
In terms of financial performance, Myriad Genetics Inc. observed improvements in several key areas during the fiscal fourth quarter of 2023. The company reported a decreased loss per share, with $-0.36 per share compared to $-0.52 in the previous year. Additionally, the earnings per share (EPS) improved from $-0.75 per share in the preceding reporting season.
The revenue for the fiscal fourth quarter of 2023 increased by 10.574% to $196.60 million from $177.80 million in the same reporting season a year before. Sequentially, the revenue advanced by 2.449% from $191.90 million. Furthermore, the company reported a net shortfall of $-31.200 million, which indicates an improvement compared to the $-42.300 million loss in the same reporting season a year ago.

Clinical Study

Breaking Barriers: Unleashing the Potential of MRD Monitoring across Varied Cancer Landscapes

Published Tue, Feb 27 2024 2:15 PM UTC

In a remarkable collaboration between Myriad Genetics and the National Cancer Center Hospital East in Japan, the stage is set for a transformative clinical trial: SCRUM-MONSTAR-SCREEN-3. This innovative study aims to revolutionize the way we monitor minimal residual disease (MRD) across various cancer types. Central to this trial is the utilization of Myriad's cutting-edge P...

Management Changes

Myriad Genetics Appoints Renowned Physician to Lead Women's Health Division Amidst Company Challenges

Published Thu, Feb 15 2024 9:05 PM UTC



In a move aimed at bolstering its position in the field of genetic testing and precision medicine, Myriad Genetics, Inc. (NASDAQ: MYGN) has appointed esteemed physician Dr. Dallas Reed as the Principal Medical Advisor to its women's health business unit. Effective immediately, Dr. Reed's appointment is seen as a strategic decision by the company to navigate through...

Merger and Acquisition

Myriad Genetics Expands Precision Medicine Portfolio: Unlocking New Avenues with Recent Acquisition

Published Thu, Feb 1 2024 2:25 PM UTC


Introduction
Myriad Genetics, a renowned player in the field of genetic testing and precision medicine, has recently completed the acquisition of select assets from Intermountain Precision Genomics (IPG). The acquisition encompasses the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah. This move is set to significa...

Merger and Acquisition

Myriad Genetics Expands Genetic Testing and Precision Medicine Capabilities with Acquisition of Precise Tumor, Precise Liquid, and Laboratory Assets from Intermountain Precision Genomics

Published Thu, Jan 18 2024 11:10 PM UTC



In a groundbreaking move that is set to revolutionize the field of genetic testing and precision medicine, Myriad Genetics, Inc. has announced its strategic acquisition of select assets from Intermountain Precision Genomics (IPG). This acquisition includes the highly coveted Precise Tumor Test, Precise Liquid Test, and IPG's CLIA-certified laboratory located in St....






 

Myriad Genetics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Myriad Genetics Inc does not provide revenue guidance.

Earnings Outlook
Myriad Genetics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com